Waiting
Login processing...

Trial ends in Request Full Access Tell Your Colleague About Jove
Journal / Medicine / Induction of Invasive Transitional Cell Bladder…
JoVE Journal
Medicine

A subscription to JoVE is required to view this content. Sign in or start your free trial.

JoVE Journal Medicine
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice
 

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Article DOI: 10.3791/50868-v • 11:02 min • October 30th, 2013
October 30th, 2013 •
1, 1, 2, 1, 1, 1, 3, 1
1Department of Internal Medicine, Division of Hematology and Oncology, University of California, Davis, 2Comparative Pathology Laboratory, UC Davis School of Veterinary Medicine, University of California, Davis, 3Merck Serono Research, Merck KGaA, Darmstadt, Germany

Chapters

Summary
Automatic Translation

An N-butyl-N-(4-hydroxybutyl)nitrosamine-induced bladder cancer model was developed in human mucin 1 (MUC1) transgenic mice for the purpose of testing MUC1-directed immunotherapy. After administering a MUC1-targeted peptide vaccine, a cytotoxic T lymphocyte response to MUC1 was confirmed by measuring serum cytokine levels and T-cell specific activity.

Tags

Keywords: Bladder Cancer Transitional Cell Carcinoma Squamous Cell Carcinoma MUC1 Transgenic N-butyl-N-(4-hydroxybutyl)nitrosamine Cytokines Immunotherapy Peptide Vaccine T-cell Response
Read Article

Get cutting-edge science videos from JoVE sent straight to your inbox every month.

Waiting X
Simple Hit Counter